Brief: Kamada Announces Expansion Of Pivotal Phase 3 Clinical Trial Of Inhaled AAT
17/05/2022 12:13
May 17 (Reuters) - Kamada Ltd KMDA.TA :
* KAMADA ANNOUNCES EXPANSION OF PIVOTAL PHASE 3 CLINICAL TRIAL OF INHALED
AAT TO
ADDITIONAL SIX CLINICAL SITES ACROSS EUROPE; AND POSITIVE RECOMMENDATION BY DSMB
TO CONTINUE THE TRIAL WITHOUT MODIFICATION
Source text for Eikon: ID:nGNX9VTcH9
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06